Cytokinetics has announced that its experimental drug aficamten, currently in trials as a potential treatment for obstructive hypertrophic cardiomyopathy, has received breakthrough therapy designation from the FDA. This designation is awarded by the FDA to certain drugs which may offer substantial improvement to patients over available therapies. The designation could shorten the FDA approval process for the drug by about 4 months.
You can read more about Cytokinetics and aficamten in these older posts from HCMBeat:
Interview with Dr. Martin Maron about Cytokinetic’s Drug Aficamten
Cytokinetics Announces Positive Results from REDWOOD-HCM Phase 2 Clinical Trial
Cytokinetics Moves Forward with HCM Drug Trial
Cytokinetics Announces its Phase 2 Clinical Trial
Positive Signs from REDWOOD-HCM
HCM Clinical Trials – the Latest News
2 Companies Testing Drugs for HCM
Scientists Get $10 Million Grant to Develop HCM Treatments
HCM Beat 
5 thoughts on “Aficamten Gets “Breakthrough Drug” Status from FDA”